Basic Information
INFLUVAC, suspension for injection 0.5ml
INJECTION, SUSPENSION
Regulatory Information
SIN13177P
January 17, 2006
Prescription Only
Therapeutic
SUBCUTANEOUS, INTRAMUSCULAR
August 10, 2023
May 30, 2025
XJ07BB02
Company Information
ABBOTT LABORATORIES (SINGAPORE ) PRIVATE LIMITED
ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED
Active Ingredients
Strength: 15mcg HA/0.5ml
Strength: 15mcg HA/0.5ml
Strength: 15mcg HA/0.5 ml
Detailed Information
Contraindications
**3.3 Contraindications** Hypersensitivity to the active substances, to any of the excipients listed in section 5.1 or to any component that may be present as traces such as eggs (ovalbumin, chicken proteins), formaldehyde, cetyltrimethylammonium bromide, polysorbate 80, or gentamicin – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. Immunisation shall be postponed in patients with febrile illness or acute infection.
Indication Information
**3.1 Therapeutic indications** Prophylaxis of influenza; especially those who run an increased risk of associated complications. Influvac® 2021 is indicated in adults and children from 6 months of age. The use of Influvac® 2021 should be based on official recommendations. Vaccination is particularly recommended for the following categories of patients, depending on national immunization policies: - Persons aged ≥ 65 years, regardless their health condition. - Adults and children with chronic disorders of the pulmonary or cardiovascular systems, including asthma. - Adults and children with chronic metabolic diseases such as diabetes mellitus. - Adults and children with chronic renal dysfunction. - Adults and children with immunodeficiencies due to disease or immunosuppressant medication (e.g., cytostatics or corticosteroids) or radiotherapy. - Children and teenagers (6 months – 18 years) who receive long-term acetylsalicylic acid containing medication, and might therefore be at risk for developing Reye’s syndrome following an influenza infection.